![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/talicia-launched-in-the-united-arab-emirates-302227318.html
https://www.prnewswire.com/news-releases/newly-published-positive-phase-3-data-demonstrates-64-increased-efficacy-with-redhills-rhb-104-in-crohns-disease-302212188.html
https://www.prnewswire.com/news-releases/redhill-biopharma-strengthens-cash-balance-settles-obligations-and-removes-talicia-lien-302202563.html
https://www.prnewswire.com/news-releases/redhill-biopharma-terminates-license-agreement-for-aemcolo-302191969.html
https://www.prnewswire.com/news-releases/redhill-announces-a-new-patent-covering-opaganib-in-combination-with-immune-checkpoint-inhibitors-valid-through-2040-302161731.html
https://www.prnewswire.com/news-releases/redhill-announces-new-opaganib-chinese-patent-against-ebola-virus-valid-through-2035-302136648.html
https://www.prnewswire.com/news-releases/redhill-announces-first-patient-enrolled-in-us-government-supported-covid-19-study-302126003.html
https://www.prnewswire.com/news-releases/redhill-biopharma-announces-full-year-2023-results-and-operational-highlights-302110455.html
https://www.prnewswire.com/news-releases/redhill-biopharma-announces-1-25-million-registered-direct-offering-at-a-premium-to-market-price-302105607.html
https://www.prnewswire.com/news-releases/redhill-announces-new-uspto-patent-covering-talicia-through-2034-302085225.html